Advertisement
Monday, Sep 27, 2021
Outlook.com
Outlook.com

Delhi, Maharashtra Among 5 States To Get First Batch of Covid Drug Remdesivir

The drug is anticipated to play a significant role in bringing down the mortality rates caused by Covid-19, given its proven positive clinical outcomes, the company said.

Delhi, Maharashtra Among 5 States To Get First Batch of Covid Drug Remdesivir
Remdesivir
Delhi, Maharashtra Among 5 States To Get First Batch of Covid Drug Remdesivir
outlookindia.com
2020-06-25T16:15:11+05:30

Domestic pharma giant Hetero has started delivering the generic version of 20,000 vials of Covifor (Remdesivir) across the country. The product is priced at Rs 5,400 per vial.

The top drug regulator granted permission to Hetero and another pharmaceutical firm for marketing authorisation of anti-viral drug Remdesivir only for "restricted emergency use" on hospitalised COVID-19 patients with moderate disease (those on oxygen).

"The first set of 20,000 vials in two equal lots of 10,000 each, one of which, will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra," ANI news agency quoted Hetero Company spokesperson as saying.

While the other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week's time, in order to meet the emergency requirements, said the spokesperson.

Covifor is the first generic brand of Remdesivir which is indicated for the treatment of Covid-19 patients in adults and children, hospitalised with severe symptoms of the disease. The drug is available in 100 mg vial (injectable). It needs to be administered intravenously in a hospital, or critical care setting, under the supervision of a registered medical practitioner. 

Covifor is anticipated to play a significant role in bringing down the mortality rates caused by Covid-19, given its proven positive clinical outcomes, the company added.

The drug is available in 100 mg vial (Injectable). It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner.

The Union Health Ministry in its fresh clinical management protocol for COVID-19 patients, has described the use of Remdesivir as investigational therapy.

Patients can be administered with 200 mg IV on day 1 followed by 100 mg IV daily for 5 days. The drug cannot be administered to a pregnant or lactating mother and children below the age of 12 years. Also, patients should not have liver problems and renal complications, stated the health ministry document.

Last month, the Central Drug Control Standard Organisation (CDCSO) office of DCGI had granted its permission to US-based Gilead Sciences for marketing authorization of its anti-viral drug Remdesivir in India for "restricted emergency use" on hospitalized COVID-19 patients in the wake of coronavirus pandemic. 

(With ANI Inputs)

Advertisement

Outlook Newsletters

Advertisement

Read More from Outlook

Bharat Bandh: Farmers Happy With 'Good Start' To Nationwide Strike Call

Bharat Bandh: Farmers Happy With 'Good Start' To Nationwide Strike Call

Reports from states claim farmers have blocked highways at various places, while traders in many small towns and cities have kept the shops closed in support.

PM Modi Launches National Digital Mission To Ensure Health IDs For All: Here Is How It Works

PM Modi Launches National Digital Mission To Ensure Health IDs For All: Here Is How It Works

The Ayushman Bharat Digital Mission is being implemented in a pilot phase in six Union Territories at present, and it has been rolled out by PM Narendra Modi for entire nation today.

‘Sports NFTs Are A Movement, Not Just A Meme’

‘Sports NFTs Are A Movement, Not Just A Meme’

The sports NFT market is brand new with tremendous potential and is growing fast, says Sidarttha Bezbora.

'Stop Distortion Of Rajput History': King Mihir Bhoj’s Descendent To Modi Govt

'Stop Distortion Of Rajput History': King Mihir Bhoj’s Descendent To Modi Govt

Kunwar Arunoday Singh Parihar, prince of Madhya Pradesh's Nagod estate, has raised objections to the Gujjar community's recent claims of having descended from King Bhoj.

Advertisement